Rare Tumors (Jul 2011)

Efficacy of trabectedin in metastatic solitary fibrous tumor

  • Xavier Pivot,
  • Laura Mansi,
  • Stephanie Servagi-Vernat,
  • Delphine Delroeux,
  • Julien Pauchot,
  • Lionel Aherfi,
  • Nicolas Isambert,
  • Christine Fagnoni-Legat,
  • Elsa Kalbacher,
  • Antoine Thiery-Vuillemin,
  • Loic Chaigneau

DOI
https://doi.org/10.4081/rt.2011.e29
Journal volume & issue
Vol. 3, no. 3
pp. e29 – e29

Abstract

Read online

Solitary fibrous tumor is a rare tumor type and has an unpredictable course. Local recurrence rate varies between 9 and 19 %, and rate of metastatic involvement between 0 and 36 %. It is characterized by a typical architecture and immuno-histochemistry tests. The most important prognostic factor is the complete resection of primary tumor. Treatment of recurrences is not clearly established. If a solitary fibrous tumor is too advanced to allow surgical resection, radiotherapy and chemotherapy may be used. The most often used drugs are doxorubicine andor ifosfamide. We report the case of man with metastatic solitary fibrous tumor treated with trabectedin, administered at a dose of 1.5 mg/m² every 3 weeks. After 3 cycles, metastases had significantly decreased. Recurrence of the disease was demonstrated 8 months after the start of trabectedin. This case shows that trabectedin is a possible treatment option.

Keywords